ST Pharm - Public Comps and Valuation Multiples

ST Pharm Overview

About ST Pharm

St Pharm Co Ltd offers custom manufacturing services of Active pharmaceutical ingredients and their intermediates for their use in pharmaceutical development and be compliant to cGMP, requirements. The firm’s business areas include commercial manufacturing of new drug development, manufacturing of generic active pharmaceutical ingredients, fine chemical’s business and development of oligonucleotide therapeutics. The company’s products comprise small molecule active pharmaceutical ingredients, Anti-cancer, Anti- coagulant active pharmaceutical ingredients, etc.

Founded

2008

HQ

Employees

n/a

Website

stpharm.co.kr

Sectors

Contract Research & Manufacturing
Small Molecules
BioTech
DeepTech

Financials

LTM Revenue $223M

LTM EBITDA $50.5M

EV

$1.4B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

ST Pharm Financials

As of September 2025, ST Pharm reported last 12-month revenue of $223M and EBITDA of $50.5M.

In the same period, ST Pharm generated $81.9M in LTM gross profit and $25.6M in net income.

See ST Pharm valuation multiples based on analyst estimates

ST Pharm P&L

In the most recent fiscal year, ST Pharm reported revenue of $192M and EBITDA of $53.2M.

ST Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX

See ST Pharm valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$223M	XXX	$192M	XXX	XXX	XXX
Gross Profit	$81.9M	XXX	$67.3M	XXX	XXX	XXX
Gross Margin	37%	XXX	35%	XXX	XXX	XXX
EBITDA	$50.5M	XXX	$53.2M	XXX	XXX	XXX
EBITDA Margin	23%	XXX	28%	XXX	XXX	XXX
EBIT	$31.5M	XXX	$19.4M	XXX	XXX	XXX
EBIT Margin	14%	XXX	10%	XXX	XXX	XXX
Net Profit	$25.6M	XXX	$24.3M	XXX	XXX	XXX
Net Margin	12%	XXX	13%	XXX	XXX	XXX
Net Debt	XXX	XXX	$36.4M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for ST Pharm including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $223M. EBITDA for the last twelve months was $50.5M. In the most recent fiscal year, ST Pharm achieved $192M in revenue and $53.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$223M	Analyst estimates available to subscribers	$192M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$81.9M	Analyst estimates available to subscribers	$67.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	36.8% gross margin	Analyst estimates available to subscribers	35.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$50.5M	Analyst estimates available to subscribers	$53.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	22.7% EBITDA margin	Analyst estimates available to subscribers	27.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$31.5M	Analyst estimates available to subscribers	$19.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	14.2% EBIT margin	Analyst estimates available to subscribers	10.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$25.6M	Analyst estimates available to subscribers	$24.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	11.5% net profit margin	Analyst estimates available to subscribers	12.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$36.4M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for ST Pharm

This financial data table provides comprehensive performance metrics for ST Pharm, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

ST Pharm generated $223M in revenue over the last twelve months.
The company achieved $50.5M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $81.9M.
Net income over the last twelve months reached $25.6M.

Fiscal Year Performance

In the most recent fiscal year, ST Pharm reported $192M in total revenue.
Fiscal year EBITDA was $53.2M.
The company maintained a gross profit margin of 35.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 27.8%.
Net profit margin reached 12.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for ST Pharm. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

ST Pharm Stock Performance

ST Pharm has current market cap of KRW 1.95T (or $1.4B), and EV of KRW 1.98T (or $1.4B).

Market Cap Evolution

ST Pharm Stock Data

As of October 17, 2025, ST Pharm's stock price is KRW 96800 (or $68).

See ST Pharm trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.4B	$1.4B	XXX	XXX	XXX	XXX	$1.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

ST Pharm Valuation Multiples

ST Pharm's trades at 7.2x EV/Revenue multiple, and 26.0x EV/EBITDA.

See valuation multiples for ST Pharm and 15K+ public comps

ST Pharm Financial Valuation Multiples

As of October 17, 2025, ST Pharm has market cap of $1.4B and EV of $1.4B.

Equity research analysts estimate ST Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

ST Pharm has a P/E ratio of 53.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$1.4B	XXX	$1.4B	XXX	XXX	XXX
EV (current)	$1.4B	XXX	$1.4B	XXX	XXX	XXX
EV/Revenue	6.2x	XXX	7.2x	XXX	XXX	XXX
EV/EBITDA	27.4x	XXX	26.0x	XXX	XXX	XXX
EV/EBIT	43.9x	XXX	71.5x	XXX	XXX	XXX
EV/Gross Profit	16.9x	XXX	n/a	XXX	XXX	XXX
P/E	53.3x	XXX	56.2x	XXX	XXX	XXX
EV/FCF	102.9x	XXX	75.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ST Pharm Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

ST Pharm Margins & Growth Rates

ST Pharm's last 12 month revenue growth is 19%

ST Pharm's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

ST Pharm's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ST Pharm's rule of X is 71% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for ST Pharm and other 15K+ public comps

ST Pharm Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	19%	XXX	20%	XXX	XXX	XXX
EBITDA Margin	23%	XXX	28%	XXX	XXX	XXX
EBITDA Growth	25%	XXX	21%	XXX	XXX	XXX
Rule of 40	38%	XXX	47%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	71%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	2%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	8%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	25%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial